Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer

BACKGROUND: Darolutamide, a structurally distinct androgen receptor inhibitor approved for the treatment of men with nonmetastatic castration-resistant prostate cancer (nmCRPC), has been shown to increase metastasis-free survival among men with nmCRPC compared with placebo. This treatment has a nove...

Descripción completa

Detalles Bibliográficos
Autores principales: Appukkuttan, Sreevalsa, Farej, Ryan, Miles, LaStella, Purser, Molly, Wen, Lonnie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394191/
https://www.ncbi.nlm.nih.gov/pubmed/33141615
http://dx.doi.org/10.18553/jmcp.2020.20330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394191/
https://www.ncbi.nlm.nih.gov/pubmed/33141615
http://dx.doi.org/10.18553/jmcp.2020.20330

Ejemplares similares